<DOC>
	<DOC>NCT01153269</DOC>
	<brief_summary>The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patients.</brief_summary>
	<brief_title>Long-term Effectiveness and Safety in Hepatitis-co-infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Ritonavir</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<criteria>Patients infected by HIV1 and HBV or HCV Age â‰¥18 years Patients who were initiated on a LPV/r containing antiretroviral (ARV) regimen Contraindications as described in SmPC (summary of product characteristics) at the time of prescription</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Co-infection with Hepatitis B or Hepatitis C</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Effectiveness</keyword>
</DOC>